All funds

Wellington Global Health Care Equity Fund USD D Ac

Equity fund

1 year

Region

USA

Largest region

Medium

Risk

Cost

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Description

  • Porteføljen søker langsiktig avkastning. Porteføljen investerer primært, enten direkte eller indirekte via derivater, i aksjer og andre verdipapirer med aksjekjennetegn (som preferanseaksjer, konvertible verdipapirer eller innskuddsbevis) utstedt av selskaper aktive innen helseomsorgsområdet verden over med markedskapitalisering normalt over USD 1 milliard. Porteføljen følger en nedenfra-og-opp aksjevalgsholdning. Mens det ikke er noen restriksjoner når det gjelder porteføljens evne til å bruke derivater for investeringsformål (som å få eksponering mot et verdipapir), bruker porteføljen primært derivater for å sikre (redusere) risikoen.
    Read more

Investment horizon

  • Wellington Global Health Care Equity Fund USD D Ac is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • Price/NAV

    12 Jun 2025

  • Start date
    29 Sept 2006
  • ISIN
    IE00B00LSD17

Risk

  • Medium (4 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Costs

  • Ongoing costs

    Includes management fees of 1,25 %

  • Platform fee
  • Kickback fee
  • Annual running costs
  • Performance-based fee

  • Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.

Allocation

  • Stocks 97%
    Interest 3%

Portfolio

Shows the fund's largest investments.

  • Eli Lilly and Co
    9.3%
  • UnitedHealth Group Inc
    5.8%
  • AstraZeneca PLC
    5.1%
  • Merck & Co Inc
    3.9%
  • Boston Scientific Corp
    3.8%
  • Vertex Pharmaceuticals Inc
    3.4%
  • Novo Nordisk AS Class B
    3.3%
  • Intuitive Surgical Inc
    3.0%
  • Johnson & Johnson
    2.9%
  • argenx SE
    2.8%